Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.

OBJECTIVE To provide primary care clinicians with a better understanding of management issues in panic disorder and guide clinical practice with recommendations for appropriate pharmacotherapy. PARTICIPANTS The 4 members of the International Consensus Group on Depression and Anxiety were James C. Ballenger (chair), Jonathan R. T. Davidson, Yves Lecrubier, and David J. Nutt. Four faculty invited by the chairman also participated: David S. Baldwin, Johan A. den Boer, Siegfried Kasper, and M. Katherine Shear. EVIDENCE The consensus statement is based on the 6 review papers that are published in this supplement and on the scientific literature relevant to these issues. CONSENSUS PROCESS There were group meetings held during a 2-day period. On day 1, the group discussed each review paper and the chairman and discussant (Dr. Kasper) identified key issues for further debate. On day 2, the group discussed these key issues to arrive at a consensus view. After the group meetings, the consensus statement was drafted by the chairman and approved by all attendees. CONCLUSIONS The consensus statement provides standard definitions for response and remission and identifies appropriate strategy for the management of panic disorder in a primary care setting. Serotonin selective reuptake inhibitors are recommended as drugs of first choice with a treatment period of 12 to 24 months. Pharmacotherapy should be discontinued slowly over a period of 4 to 6 months.

[1]  James C.Ballenger.  Selective Serotonin Reuptake Inhibitors in Panic Disorder , 1999 .

[2]  Y. Lecrubier,et al.  Panic and depression: a worldwide primary care perspecctive , 1998, International clinical psychopharmacology.

[3]  J. Ballenger,et al.  Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. , 1998, The American journal of psychiatry.

[4]  M K Shear,et al.  Multicenter collaborative panic disorder severity scale. , 1997, The American journal of psychiatry.

[5]  J. Rosenbaum,et al.  Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. , 1997, Journal of clinical psychopharmacology.

[6]  U. Lepola,et al.  The effect of Citalopram in panic disorder , 1997, British Journal of Psychiatry.

[7]  Y. Lecrubier,et al.  Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder , 1997 .

[8]  Y. Lecrubier,et al.  A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder , 1997, Acta psychiatrica Scandinavica.

[9]  M. Bousoño,et al.  SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. , 1997, Journal of sex & marital therapy.

[10]  D. Baldwin,et al.  Effects of antidepressant drugs on sexual function. , 1997, International journal of psychiatry in clinical practice.

[11]  M. Albus,et al.  Predictors of outcome in panic disorder: a 5-year prospective follow-up study. , 1996, Journal of Affective Disorders.

[12]  Trevor R. Norman,et al.  Diazepam versus alprazolam for the treatment of panic disorder. , 1996, The Journal of clinical psychiatry.

[13]  D. Cowley,et al.  Long-term course and outcome in panic disorder: a naturalistic follow-up study. , 1996, Anxiety.

[14]  K. Behnke,et al.  Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study , 1995, British Journal of Psychiatry.

[15]  R. Kessler,et al.  Panic and panic disorder in the United States. , 1994, The American journal of psychiatry.

[16]  Lépine,et al.  L'épidémiologie des troubles anxieux et dépressifs dans une population générale française. , 1994 .

[17]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[18]  V. Starcevic,et al.  Comorbidity in panic disorder: II. Chronology of appearance and pathogenic comorbidity , 1993, Psychiatry Research.

[19]  J. Lépine,et al.  Suicide attempts in patients with panic disorder. , 1993, Archives of general psychiatry.

[20]  K. Rickels,et al.  Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. , 1993, Archives of general psychiatry.

[21]  D. Black,et al.  A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. , 1993, Archives of general psychiatry.

[22]  P. Lavori,et al.  Comorbidity of panic and major depressive disorder. , 1993, Journal of psychiatric research.

[23]  G. Klerman.  Drug Treatment of Panic Disorder , 1992, British Journal of Psychiatry.

[24]  W A Ray,et al.  Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. , 1992, American journal of epidemiology.

[25]  E. Eriksson,et al.  Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. , 1992, Journal of clinical psychopharmacology.

[26]  J. Brophy,et al.  The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. , 1992, Journal of affective disorders.

[27]  R. Rubin,et al.  A Fixed‐Dose Study of Alprazolam 2 mg, Alprazolam 6 mg, and Placebo in Panic Disorder , 1992, Journal of clinical psychopharmacology.

[28]  P. Bech,et al.  Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study , 1991, Acta psychiatrica Scandinavica. Supplementum.

[29]  J. Rosenbaum,et al.  Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. , 1991, The Journal of clinical psychiatry.

[30]  M. Stein,et al.  Major depression in patients with panic disorder: factors associated with course and recurrence. , 1990, Journal of affective disorders.

[31]  M Fier,et al.  Panic disorder and agoraphobia. , 1990, New Jersey medicine : the journal of the Medical Society of New Jersey.

[32]  R. Noyes.  The comorbidity and mortality of panic disorder. , 1990, Psychiatric medicine.

[33]  D. Munjack,et al.  Alprazolam, Propranolol, and Placebo in the Treatment of Panic Disorder and Agoraphobia with Panic Attacks , 1989, Journal of clinical psychopharmacology.

[34]  M. Stein,et al.  Social phobic symptoms in patients with panic disorder: practical and theoretical implications. , 1989, The American journal of psychiatry.

[35]  R. Swinson,et al.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. , 1988, Archives of general psychiatry.

[36]  A. Rifkin,et al.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. , 1988, Archives of general psychiatry.

[37]  H. Wittchen,et al.  Panic and phobias : empirical evidence of theoretical models and longterm effects of behavioral treatments , 1986 .

[38]  H. Wittchen.  Epidemiology of Panic Attacks and Panic Disorders , 1986 .

[39]  T. Rosenthal,et al.  Anxious depressions. Clinical, family history, and naturalistic outcome--comparisons with panic and major depressive disorders. , 1984, Journal of affective disorders.